Cost-benefit impact of free asthma medication provision for the pediatric population.

CONCLUSION: The economic burden of pediatric asthma on Brazil's public health care system is significant. From 2012 to 2015, free provision of inhaled corticosteroid was cost-effective in all age groups. In 2017, no cost-benefit effect was observed in this population, but asthma admission rate decreased. PMID: 32217290 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32217290?dopt=Abstract

Source: Respiratory Care - March 30, 2020 Category: Respiratory Medicine Authors: Koltermann V, Friedrich FO, Fensterseifer AC, Ongaratto R, Pinto LA Tags: Respir Med Source Type: research